Expression and Clinical Significance of Cyclooxygenase-2 in Breast Cancer: A Meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

 LI Man ¹ , JU Lirong ¹ , XU Lina ²

1. School of Public Health and Family Medicine, Capital Medical University, Beijing 100069, China;2. Haidian District Center for Disease Prevention and Control, Beijing 100094, China;

Corresponding author：

LI Man, Email: liman720820@yahoo.com.cn

Keywords：

Cyclooxygenase-2 expression; Breast cancer; Systematic review; Meta-analysis; Case-control study

DOI：

10.7507/1672-2531.20110094

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective 　To investigate the expression and clinical significance of cyclooxygenase-2 (COX-2) in human breast cancer with meta-analyses.
Methods 　The published studies were searched in the CBM, CNKI, VIP and WanFang databases, and other relevant journals were also handsearched to identify all the relevant case-control trials. The quality of the included studies was assessed. The Cochrane Collaboration’s software RevMan 4.2.10 was used to test the heterogeneity, overall effect and publication bias of the combined studies.
Results 　A total of 8 studies were recruited. As for the positive rate of COX-2 expression, significant differences were tested between breast cancer vs. normal breast tissues, cell differentiation G1 vs. cell differentiation G2-G3 with OR (95%CI) at 16.36 (9.18, 29.15) and 0.34 (0.18, 0.63), respectively. No significant difference was tested between lymph node metastasi vs. non-lymph node metastasi, clinical stages I-II vs. clinical stages III-IV with OR (95%CI) at 1.36 (0.61, 3.03) and 0.61 (0.34, 1.10), respectively.
Conclusion 　According to the domestic evidence, COX-2 may be participated the whole course of carcinogenesis of breast cancer, but is not the absolute factor for estimating the survival rate of the patients with breast cancer, and more high-quality studies are expected for further study.

Citation： LI Man,JU Lirong,XU Lina. Expression and Clinical Significance of Cyclooxygenase-2 in Breast Cancer: A Meta-analysis. Chinese Journal of Evidence-Based Medicine, 2011, 11(5): 524-528. doi: 10.7507/1672-2531.20110094 Copy

1.	1 Watanabe O, Shimizu T, Imamura H, et al . Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res , 2003, 23(4): 3215-3221.
2.	2 Cejas P, Garcia-Cabezas MA, Casado E, et al . Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium. Clin Transl Oncol , 2005, 7(6): 239-243.
3.	3 Ristimaki A, Sivula A, Lundin J, et al . Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res , 2002, 62(3): 632-635.
4.	4 Park K, Han S, Shin E, et al . Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol , 2006, 32(10): 1093-1096.
5.	6 Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer , 2004, 4(6): 428-433.
6.	14 McCarthy K, Bustin SA, Ogunkolade B, et al . Cyclooxygenase-2(COX-2) mRNA expression and hormone receptor status in breast cancer. Eur J Surg Oncol , 2006, 32(7): 707-709.
7.	15 Kelly LM, Hill AD, Kennedy S, et al . Lack of prognostic effect of cyclooxygenase-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol , 2003, 29(9): 707-710.
8.	16 Lichtenstein MJ, Mulrow CD, Elwood PC, et al . Guidelines for reading case control studies. J Chronic Dis , 1987, 40(9): 893-903.
9.	17 Chell S, Kaidi A, Williams AC, et al . Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta , 2006, 1766(1): 104-119.
10.	郭雪西. 乳腺癌中环氧化酶-2和CD105的表达. 中华临床医学研究杂志, 2006, 12(11): 1241-1242.
11.	吴迪, 吴勇, 任立群, 等. 乳腺癌和腋窝淋巴结转移癌组织中COX-2的表达及意义. 吉林大学学报(医学版), 2007, 33(5): 894-897.
12.	王西京, 代志军, 赵世平. 乳腺癌组织中环氧化酶-2的表达及其意义. 肿瘤防治杂志, 2004, 11(12): 1261-1263.
13.	欧阳周, 胡春宏, 汪安兰, 等. 环氧合酶-2在乳腺癌中的表达及临床意义. 世界肿瘤杂志, 2007, 6(2): 101-106.
14.	罗智勇, 吴亚群, 张林, 等. c-erbB-2和cox-2在乳腺癌中的表达及其意义. 中国普通外科杂志, 2004, 13(5): 372-375.
15.	许淼, 王杨, 阎秀欣. 环氧化酶-2在乳腺癌组织中的表达及其临床意义. 肿瘤研究与临床, 2007, 19(5): 311-313.
16.	周士珍, 吴强, 吴正升, 等. 乳腺癌中环氧化酶-2的表达及其与VEGF、MVD、MMP-9、TIMP-1的关系. 临床与实验病理学杂志, 2005, 21(4): 442-445.
17.	郑希民, 张小纲, 吴迪. 环氧化酶-2在乳腺癌组织的表达研究. 中国妇幼保健, 2007, 22(10): 1408-1410.
18.	王丽辉, 王波, 李连宏, 等. 乳腺癌VEGF、MMP-9及COX-2蛋白表达与淋巴道转移和血管生成的相关性. 临床与实验病理学杂志, 2008, 24(2): 154-157.
19.	高砚春, 吴诚义. COX-2、VEGF-C在乳腺癌中的表达及与淋巴转移的关系. 重庆医科大学学报, 2007, 32(9): 915-918.
20.	宋印利, 孙淑娟, 张清媛. COX-2与VEGF在乳腺癌中的表达及临床意义. 当代医学(学术版), 2008, 63(3): 98-99.
21.	李鹏, 滕月娥, 仆欣, 等. COX-2和VEGF-C在乳腺癌组织中的表达与预后的关系. 中国肿瘤临床, 2009, 36(4): 207-210.

1. 1 Watanabe O, Shimizu T, Imamura H, et al . Expression of cyclooxygenase-2 in malignant and benign breast tumors. Anticancer Res , 2003, 23(4): 3215-3221.
2. 2 Cejas P, Garcia-Cabezas MA, Casado E, et al . Localisation of COX-2 protein is different in breast ductal carcinoma and adjacent non-tumour ductal epithelium. Clin Transl Oncol , 2005, 7(6): 239-243.
3. 3 Ristimaki A, Sivula A, Lundin J, et al . Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res , 2002, 62(3): 632-635.
4. 4 Park K, Han S, Shin E, et al . Cox-2 expression on tissue microarray of breast cancer. Eur J Surg Oncol , 2006, 32(10): 1093-1096.
5. 6 Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer , 2004, 4(6): 428-433.
6. 14 McCarthy K, Bustin SA, Ogunkolade B, et al . Cyclooxygenase-2(COX-2) mRNA expression and hormone receptor status in breast cancer. Eur J Surg Oncol , 2006, 32(7): 707-709.
7. 15 Kelly LM, Hill AD, Kennedy S, et al . Lack of prognostic effect of cyclooxygenase-2 expression in primary breast cancer on short-term follow-up. Eur J Surg Oncol , 2003, 29(9): 707-710.
8. 16 Lichtenstein MJ, Mulrow CD, Elwood PC, et al . Guidelines for reading case control studies. J Chronic Dis , 1987, 40(9): 893-903.
9. 17 Chell S, Kaidi A, Williams AC, et al . Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta , 2006, 1766(1): 104-119.
10. 郭雪西. 乳腺癌中环氧化酶-2和CD105的表达. 中华临床医学研究杂志, 2006, 12(11): 1241-1242.
11. 吴迪, 吴勇, 任立群, 等. 乳腺癌和腋窝淋巴结转移癌组织中COX-2的表达及意义. 吉林大学学报(医学版), 2007, 33(5): 894-897.
12. 王西京, 代志军, 赵世平. 乳腺癌组织中环氧化酶-2的表达及其意义. 肿瘤防治杂志, 2004, 11(12): 1261-1263.
13. 欧阳周, 胡春宏, 汪安兰, 等. 环氧合酶-2在乳腺癌中的表达及临床意义. 世界肿瘤杂志, 2007, 6(2): 101-106.
14. 罗智勇, 吴亚群, 张林, 等. c-erbB-2和cox-2在乳腺癌中的表达及其意义. 中国普通外科杂志, 2004, 13(5): 372-375.
15. 许淼, 王杨, 阎秀欣. 环氧化酶-2在乳腺癌组织中的表达及其临床意义. 肿瘤研究与临床, 2007, 19(5): 311-313.
16. 周士珍, 吴强, 吴正升, 等. 乳腺癌中环氧化酶-2的表达及其与VEGF、MVD、MMP-9、TIMP-1的关系. 临床与实验病理学杂志, 2005, 21(4): 442-445.
17. 郑希民, 张小纲, 吴迪. 环氧化酶-2在乳腺癌组织的表达研究. 中国妇幼保健, 2007, 22(10): 1408-1410.
18. 王丽辉, 王波, 李连宏, 等. 乳腺癌VEGF、MMP-9及COX-2蛋白表达与淋巴道转移和血管生成的相关性. 临床与实验病理学杂志, 2008, 24(2): 154-157.
19. 高砚春, 吴诚义. COX-2、VEGF-C在乳腺癌中的表达及与淋巴转移的关系. 重庆医科大学学报, 2007, 32(9): 915-918.
20. 宋印利, 孙淑娟, 张清媛. COX-2与VEGF在乳腺癌中的表达及临床意义. 当代医学(学术版), 2008, 63(3): 98-99.
21. 李鹏, 滕月娥, 仆欣, 等. COX-2和VEGF-C在乳腺癌组织中的表达与预后的关系. 中国肿瘤临床, 2009, 36(4): 207-210.

Chinese Journal of Evidence-Based Medicine

Expression and Clinical Significance of Cyclooxygenase-2 in Breast Cancer: A Meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content